Henry Meds Company Profile

Background

Overview

Henry Meds is a telehealth platform founded in 2022, specializing in providing affordable and accessible healthcare services, particularly focusing on weight management and hormone replacement therapies. The company operates primarily within the digital media, healthcare, and pharmaceutical sectors, aiming to simplify healthcare delivery by eliminating the need for insurance and in-person visits.

Mission and Vision

Henry Meds is committed to making healthcare more accessible and affordable for all Americans, regardless of location or financial situation. By leveraging telehealth technologies, the company seeks to provide personalized care directly to patients' homes, ensuring convenience and cost-effectiveness.

Primary Area of Focus

The company's primary focus is on weight management and hormone replacement therapies, offering treatments such as GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide) and testosterone replacement therapy. These services are delivered through a subscription-based telehealth model, providing patients with access to licensed healthcare providers and medications without the need for traditional insurance or in-person consultations.

Industry Significance

Henry Meds operates in the rapidly growing telehealth industry, which has seen significant expansion due to increased demand for remote healthcare services. By offering specialized treatments for weight management and hormone therapies, the company addresses critical health concerns prevalent in the United States, positioning itself as a significant player in the digital health space.

Key Strategic Focus

Core Objectives

• Accessibility: Provide affordable healthcare services to a broad demographic, including underserved populations.

• Convenience: Offer telehealth consultations and home delivery of medications to eliminate traditional healthcare barriers.

• Affordability: Maintain competitive pricing to make treatments accessible without insurance.

Specific Areas of Specialization

• Weight Management: Offer compounded GLP-1 receptor agonists, including semaglutide, tirzepatide, and liraglutide, in both injectable and oral forms.

• Hormone Replacement Therapy (HRT): Provide testosterone replacement therapy for individuals experiencing low testosterone levels.

Key Technologies Utilized

• Telehealth Platforms: Utilize secure video conferencing and messaging systems for patient-provider interactions.

• E-commerce Systems: Implement online subscription models for medication delivery.

• Data Analytics: Employ analytics to monitor patient outcomes and optimize treatment plans.

Primary Markets or Conditions Targeted

• Geographic Markets: Services are available in over 20 states across the U.S., with plans for further expansion.

• Medical Conditions: Focus on weight management, obesity, and testosterone deficiency.

Financials and Funding

Funding History

• Seed Investment: On October 1, 2022, Henry Meds secured seed funding led by Heron Rock Fund, indicating strong investor confidence in its business model and growth potential.

Total Funds Raised

• Specific details regarding the total funds raised are not publicly disclosed.

Notable Investors

• Heron Rock Fund: Led the seed investment round, reflecting a strategic interest in telehealth and digital health solutions.

Intended Utilization of Capital

• Platform Development: Enhance telehealth infrastructure to improve patient experience.

• Market Expansion: Extend services to additional states and demographics.

• Regulatory Compliance: Ensure adherence to healthcare regulations and standards.

Pipeline Development

Key Pipeline Candidates

• Compounded Semaglutide: A GLP-1 receptor agonist used for weight management, available in injectable and oral forms.

• Compounded Tirzepatide: Another GLP-1 receptor agonist for weight loss, offered in injectable and oral forms.

• Compounded Liraglutide: A GLP-1 receptor agonist available in injectable form.

• Testosterone Replacement Therapy: Available in injectable and oral forms for individuals with low testosterone levels.

Stages of Clinical Trials or Product Development

• As a telehealth provider, Henry Meds does not conduct clinical trials but sources medications from licensed compounding pharmacies.

Target Conditions

• Obesity and Overweight: Addressed through weight management programs.

• Hypogonadism: Treated with testosterone replacement therapy.

Relevant Timelines for Anticipated Milestones

• Service Expansion: Ongoing efforts to expand service availability to additional states.

• Regulatory Approvals: Continuous monitoring and compliance with healthcare regulations.

Technological Platform and Innovation

Proprietary Technologies

• Telehealth Platform: A secure, user-friendly interface for patient consultations and follow-ups.

• Medication Delivery System: An integrated system for processing and shipping prescriptions directly to patients.

Significant Scientific Methods

• Compounding Pharmacy Partnerships: Collaborations with licensed pharmacies to create customized medication formulations.

• Data Analytics: Utilization of data to monitor treatment efficacy and patient outcomes.

Leadership Team

Key Executive Profiles

• Dr. Steven Peacock: Chief Medical Officer, Doctor of Osteopathy, overseeing clinical operations and medical protocols.

• Dr. Elizabeth Lowden: Medical Director, Endocrinologist, responsible for medical oversight and treatment guidelines.

• Evan Johnson, PA: Clinical Team Manager, Physician Assistant, managing clinical staff and patient care coordination.

• Hee Jin Cayetano, PA: Physician Assistant, Registered Dietitian, providing clinical support and dietary guidance.

• Kaedi Fehlberg, NP: Nurse Practitioner, Clinical Team Manager, overseeing nursing staff and patient assessments.

• Rae Beltinck: Health & Wellness Manager, focusing on patient education and wellness programs.

• Trace Owens, NP: Nurse Practitioner, delivering patient care and support.

• Elizabeth Snow, NP: Nurse Practitioner, providing clinical services and patient management.

Competitor Profile

Market Insights and Dynamics

• Market Size and Growth Potential: The telehealth industry is experiencing rapid growth, with increasing adoption of remote healthcare services.

• Industry Trends: A shift towards personalized, at-home healthcare solutions and the integration of technology in medical services.

Competitor Analysis

• Orderly Meds: A direct competitor offering similar telehealth services for weight management and hormone therapies.

• Hims & Hers Health: Provides telehealth consultations and treatments for various health concerns, including weight management.

Strategic Collaborations and Partnerships

• Compounding Pharmacies: Partnerships with licensed pharmacies to provide customized medication formulations.

• Healthcare Providers: Collaborations with licensed healthcare professionals to ensure quality care delivery.

Operational Insights

• Market Position: Henry Meds positions itself as an affordable and accessible telehealth provider for weight management and hormone therapies.

• Competitive Advantages: Competitive pricing, no insurance requirements, and a focus on patient convenience.

Strategic Opportunities and Future Directions

• Service Expansion: Plans to extend services to additional states and demographics.

• Technology Integration: Enhancing telehealth platforms and data analytics capabilities.

• Regulatory Compliance: Ensuring adherence to evolving healthcare regulations and standards.

Contact Information

• Website: henrymeds.com

Note: The information provided is based on available data as of February 8, 2026.